mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern.

Autor:	Kaplonek P; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Fischinger S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Cizmeci D; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Bartsch YC; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Kang J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Burke JS; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Shin SA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Dayal D; Space Exploration Technologies Corp, Hawthorne, CA, USA., Martin P; Space Exploration Technologies Corp, Hawthorne, CA, USA., Mann C; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA., Amanat F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Julg B; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Nilles EJ; Brigham and Women's Hospital, Boston, MA, USA., Musk ER; Space Exploration Technologies Corp, Hawthorne, CA, USA., Menon AS; Space Exploration Technologies Corp, Hawthorne, CA, USA., Krammer F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Saphire EO; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA., Andrea Carfi; Moderna Inc, Cambridge, MA, USA., Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. Electronic address: galter@mgh.harvard.org.
Jazyk:	angličtina
Zdroj:	Immunity [Immunity] 2022 Feb 08; Vol. 55 (2), pp. 355-365.e4. Date of Electronic Publication: 2022 Jan 06.
DOI:	10.1016/j.immuni.2022.01.001
Abstrakt:	SARS-CoV-2 mRNA vaccines confer robust protection against COVID-19, but the emergence of variants has generated concerns regarding the protective efficacy of the currently approved vaccines, which lose neutralizing potency against some variants. Emerging data suggest that antibody functions beyond neutralization may contribute to protection from the disease, but little is known about SARS-CoV-2 antibody effector functions. Here, we profiled the binding and functional capacity of convalescent antibodies and Moderna mRNA-1273 COVID-19 vaccine-induced antibodies across SARS-CoV-2 variants of concern (VOCs). Although the neutralizing responses to VOCs decreased in both groups, the Fc-mediated responses were distinct. In convalescent individuals, although antibodies exhibited robust binding to VOCs, they showed compromised interactions with Fc-receptors. Conversely, vaccine-induced antibodies also bound robustly to VOCs but continued to interact with Fc-receptors and mediate antibody effector functions. These data point to a resilience in the mRNA-vaccine-induced humoral immune response that may continue to offer protection from SARS-CoV-2 VOCs independent of neutralization. Competing Interests: Declaration of interests G.A. is the founder of Seromyx Systems Inc. A.C. is an employee of Moderna Inc. D.D., P.M., A.S.M., and E.R.M. are employees of Space Exploration Technologies Corp. All other authors have declared no competing interests. (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu